throbber
Olinger, Jonathan
`
`From:
`Sent:
`To:
`
`Cc:
`
`Subject:
`
`Kennedy, Michael <MKennedy@cov.com>
`Tuesday, March 21, 2017 6:18 PM
`Cobb, Jeremy; Olinger, Jonathan; Holloway, Clay; Stockwell, Mitch; Brouillette, Amanda;
`MJOFFRE@skgf.com; JCROZENDAAL@skgf.com; CVIRA@skgf.com; Delzicol-Cov
`Moore, Susie; andrea@wsfirm.com; claire@wsfirm.com; wh@wsfirm.com; George
`Pappas; Elikan, Jeffrey
`RE: Warner Chilcott, et al v Teva Pharmaceuticals USA, Inc. and Mylan Pharmaceuticals
`Inc., et al
`
`All: In view of today’s meet-and-confer, and Qualicaps’ designation of Nigel Watson to cover some topics previously
`assigned to Tanjoh-san, the below now represents the topics for which Qualicaps is designating Tanjoh-san subject to
`our objections. I have indicated changes from Jeremy’s 3/17 email with strikethrough and underline. I believe the edits
`below to topics 3, 4, and 6, and addition of 9 to the list, should address Mylan’s concerns from this morning’s call.
`
`
`• Mylan and Teva Topic 1: Tanjoh-san will provide testimony regarding the conception,
`research, development, design, manufacture, reduction to practice, and diligence
`between conception and reduction to practice of the inventions claimed by the ’180
`patent
`• Mylan and Teva Topic 2: Tanjoh-san will provide testimony regarding publications
`related to the ’180 patent.
`• Mylan and Teva Topic 3: Tanjoh-san will provide testimony regarding facts concerning
`the work on hard capsule products manufactured by Qualicaps, including but not limited
`to those that embody the invention claimed by the ’180 patent.
`• Mylan and Teva Topic 4: Tanjoh-san will provide testimony regarding the first offer for
`sale, public use, and first sale of any hard capsule products manufactured by Qualicaps
`that embody the invention claimed by the ’180 patent.
`• Mylan and Teva Topic 5: Tanjoh-san will provide testimony regarding facts concerning
`the identification of any hard capsule products manufactured by Qualicaps that
`incorporates, practices, or embodies that embody the invention claimed by the ’180
`patent.
`• Mylan and Teva Topic 6: Tanjoh-san will provide testimony regarding facts concerning
`the development of hard capsule products manufactured by Qualicaps, including failed
`attempts, that led to the are an embodiment of the ’180 patent.
`• Mylan and Teva Topic 7: Tanjoh-san will provide testimony regarding the design,
`development, first sale, and/or first offer for sale of hard capsule products
`manufactured by Qualicaps that embodies the invention claimed by the ’180 patent.
`• Mylan and Teva Topic 8: Tanjoh-san will provide testimony regarding any non-privileged
`information that is responsive to this topic.
`• Mylan and Teva Topic 9: Tanjoh-san will provide testimony regarding any non-privileged
`information that is responsive to this topic.
`• Mylan and Teva Topic 12: Tanjoh-san will provide testimony regarding facts concerning
`any assignment, license, or transfer of rights in the ’180 patent to Warner Chilcott
`Company, LLC.
`
`1
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1025 - Page 1
`
`

`

`• Mylan and Teva Topic 15: Tanjoh-san will provide testimony regarding the benefits or
`advantages of hard capsule products manufactured by Qualicaps that embody the
`invention claimed by the ’180 patent.
`• Mylan and Teva Topic 16: Tanjoh-san will provide testimony regarding the facts
`concerning this topic subject to the objections and to the extent that it does not involve
`expert testimony or a legal conclusion
`• Mylan and Teva Topic 17: Tanjoh-san will provide testimony regarding the facts
`concerning this topic subject to the objections and to the extent that it does not involve
`expert testimony or a legal conclusion
`• Mylan and Teva Topic 18: Tanjoh-san will provide testimony regarding the people at
`Qualicaps involved in the development, manufacture, sales, and licensing of any hard
`capsule products manufactured by Qualicaps that embodies the invention claimed by
`the ’180 patent. [Qualicaps will designate Mr. Watson for the portion of Topic 18
`dealing with sales and licensing].
`• Mylan and Teva Topic 21: Tanjoh-san will provide testimony regarding facts concerning
`any assignment, license, or transfer of rights in the ’180 patent to Warner Chilcott
`Company, LLC.
`• Mylan and Teva Topic 22: Tanjoh-san will provide testimony regarding this topic subject
`to our objections.
`• Mylan Topic 24 and Teva Topic 26: Tanjoh-san will provide testimony regarding this
`topic subject to our objections. [Clarification - Tanjoh-san will cover this topic as it
`relates to the topics for which he is designated, and Mr. Watson will cover this topic as it
`relates to his topics].
`• Mylan Topic 25 and Teva Topic 27: Tanjoh-san will provide testimony regarding this
`topic subject to our objections.
`• Mylan Topic 26 and Topic 28: Tanjoh-san will provide testimony regarding this topic
`subject to our objections. [Clarification - Tanjoh-san will cover this topic as it relates to
`the topics for which he is designated, and Mr. Watson will cover this topic as it relates to
`his topics].
`
`
`From: Cobb, Jeremy
`Sent: Monday, March 20, 2017 5:56 PM
`To: Olinger, Jonathan; Holloway, Clay; Stockwell, Mitch; Brouillette, Amanda; MJOFFRE@skgf.com;
`JCROZENDAAL@skgf.com; CVIRA@skgf.com; Delzicol-Cov
`Cc: Moore, Susie; andrea@wsfirm.com; claire@wsfirm.com; wh@wsfirm.com; Pappas, George; Elikan, Jeffrey;
`Kennedy, Michael
`Subject: RE: Warner Chilcott, et al v Teva Pharmaceuticals USA, Inc. and Mylan Pharmaceuticals Inc., et al
`
`Jonathan,
`
`We will be available at noon EST tomorrow. Please use the following dial-in: 1-866-798-7071 Conference Code
`13504396.
`
`Best,
`Jeremy
`
`Jeremy Cobb
`
`Covington & Burling LLP
`One CityCenter, 850 Tenth Street, NW
`
`2
`
`
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1025 - Page 2
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket